Dupixent Special Drug Use Investigation for long term use

Dupixent Special Drug Use Investigation for long term use - Dupixent Special Drug Use Investigation for long term use

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032807

Enrollment

900

Registered

2018-06-11

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients with atopic dermatitis with inadequate response to conventional therapies -Patients who newly start receiving the treatment with Dupixent -Patients who can provide informed consent

Exclusion criteria

Exclusion criteria: Subjects who are participating in or have been registered for clinical trials with therapeutic intervention to Dupixent

Design outcomes

Primary

Measure	Time frame
Safety: Incidence rates of adverse drug reactions, Safety specification items of Dupixent, asthma attack Effectiveness: Investigators global assessment (IGA), Peak weekly pruritus NRS	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance -

Sanofi K.K. Post-authorization regulatory studies, Medical Affairs

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results